SAN DIEGO, Feb. 3, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced that it has entered into a contractual agreement to provide its Decipher® prostate cancer test to FEDMED Payors. FEDMED is a national provider network that covers over 40 million lives. The Decipher prostate cancer classifier directly measures a patient's biological risk of developing metastatic prostate cancer. GenomeDx, which discovered and developed the Decipher test, will provide laboratory services to the FEDMED network. FEDMED Payors will provide insurance coverage for physicians who order the Decipher test for their patients.
"The agreement with FEDMED adds to our growing list of networks that are now providing patients access to the Decipher test, which gives physicians and their patients a tool to predict the aggressiveness of prostate cancer and clarity about the course of treatment for men after prostate surgery," said Doug Dolginow, MD, CEO of GenomeDx. "This builds on our existing coverage bringing the number of covered lives with access to Decipher to over 100 million."
The Decipher® Prostate Cancer Classifier directly measures a patient's biological risk of developing metastatic prostate cancer. By assessing the activity of multiple genomic markers associated with metastatic disease, Decipher provides information about the aggressiveness of a patient's tumor - information distinct from that provided by PSA and other clinical tools. Already tested in over 2,000 patients, Decipher continues to demonstrate that it can accurately predict aggressive disease and direct treatment decisions for men with prostate cancer.
Decipher is available to eligible US patients through their physicians and as a part of GenomeDx's ongoing program of clinical studies. To learn more about ordering the Decipher test please visit www.deciphertest.com
GenomeDx Biosciences develops and commercializes genomic tests for prostate and other urologic cancers that direct treatment decision-making, improve patient outcomes and ultimately reduce healthcare costs. GenomeDx has developed the Decipher® prostate cancer classifier, the first and only commercially available genomic test that predicts the risk of post-operatively developing metastatic prostate cancer independently of PSA and other conventional risk assessment tools. GenomeDx is based in San Diego, California and Vancouver, British Columbia.
Learn more at www.genomedx.com
FEDMED is a National Provider Network and Healthcare Financial Services Organization. FEDMED has developed innovative programs and services for the healthcare provider community in conjunction with large payors of healthcare services. FEDMED's objective is to provide significant measurable benefits to providers not available from other provider networks and managed care organizations. FEDMED's programs have been created to specifically address these challenges.
Learn more at www.fedmedinc.com
SOURCE GenomeDx Biosciences